# A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo

Source: https://onco.cc/trials/nct07101614/  
OnCo record `nct07101614` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in triple-negative breast cancer, run by Shengjing Hospital, not yet recruiting.

## Summary

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC). is a phase 2, randomised interventional study registered as NCT07101614 by Shengjing Hospital, with a registry enrolment figure of 125 participants, started 2025-09-01 and due to reach its primary completion in 2027-11-30. Interventions recorded: JS004 in combination with toripalimab and chemotherapy; Toripalimab and chemotherapy; Chemotherapy. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "In cases of multiple pathological results, the definition of triple-negative breast cancer is based on the final molecular subtype result from the last biopsy pathology". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07101614
- Phase: 2
- Setting: An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
- Sponsor: Shengjing Hospital
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT07101614: https://clinicaltrials.gov/study/NCT07101614

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07101614.json